XNASKNSA
Market cap1.49bUSD
Dec 20, Last price
20.59USD
1D
0.49%
1Q
-19.70%
IPO
6.08%
Name
Kiniksa Pharmaceuticals Ltd
Chart & Performance
P/E
105.55
P/S
5.50
EPS
0.20
Div Yield, %
0.00%
Shrs. gr., 5y
19.47%
Rev. gr., 5y
%
Revenues
270m
+22.74%
Net income
14m
-92.32%
CFO
13m
+129.05%
Earnings
Jun 05, 2025
Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 270,259 22.74% | 220,180 471.24% | 38,544 | |||||
Cost of revenue | 132,621 | 112,456 | 108,397 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 137,638 | 107,724 | (69,853) | |||||
NOPBT Margin | 50.93% | 48.93% | ||||||
Operating Taxes | (30,736) | (172,337) | 1,385 | |||||
Tax Rate | ||||||||
NOPAT | 168,374 | 280,061 | (71,238) | |||||
Net income | 14,084 -92.32% | 183,363 -216.11% | (157,924) -2.14% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (2,206) | 2,516 | 11,770 | |||||
BB yield | 0.17% | -0.24% | -1.46% | |||||
| Debt | ||||||||
Debt current | 4,506 | 3,301 | 3,381 | |||||
Long-term debt | 22,263 | 8,537 | 8,719 | |||||
Deferred revenue | 11,954 | 12,000 | ||||||
Other long-term liabilities | 1,858 | 1,839 | 270 | |||||
Net debt | (179,602) | (178,770) | (170,101) | |||||
| Cash flow | ||||||||
Cash from operating activities | 13,301 | 5,807 | (126,298) | |||||
CAPEX | (130) | (105) | (20,415) | |||||
Cash from investing activities | (29,557) | (8,078) | 128,635 | |||||
Cash from financing activities | 1,495 | 2,516 | 5,885 | |||||
FCF | 160,673 | 272,715 | (69,005) | |||||
| Balance | ||||||||
Cash | 206,371 | 190,608 | 182,201 | |||||
Long term investments | ||||||||
Excess cash | 192,858 | 179,599 | 180,274 | |||||
Stockholders' equity | (477,924) | (491,971) | (675,445) | |||||
Invested Capital | 945,086 | 19,695 | 6,368 | |||||
ROIC | 34.90% | 2,149.11% | ||||||
ROCE | 29.46% | 25.90% | ||||||
| EV | ||||||||
Common stock shares outstanding | 71,923 | 70,421 | 68,577 | |||||
Price | 17.54 17.09% | 14.98 27.27% | 11.77 -33.39% | |||||
Market cap | 1,261,528 19.59% | 1,054,911 30.70% | 807,149 -26.14% | |||||
EV | 1,081,926 | 876,141 | 637,048 | |||||
EBITDA | 139,979 | 110,126 | (67,498) | |||||
EV/EBITDA | 7.73 | 7.96 | ||||||
Interest | 1,253 | |||||||
Interest/NOPBT | 1.16% | |||||||